Celgene Corporation today announced that findings from ongoing clinical trials of OTEZLA , the Company’s oral, selective inhibitor of phosphodiesterase 4 , conducted in patients with moderate or moderate to severe plaque psoriasis, and in adult patients with active psoriatic arthritis, will be presented at the 75th Annual Meeting of the American Academy of Dermatology in Orlando, Florida. Ten abstracts will be presented at the meeting.